Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants
Tomiko Oskotsky, Ivana Marić, Alice Tang, et al.
JAMA Network Open (2021) Vol. 4, Iss. 11, pp. e2133090-e2133090
Open Access | Times Cited: 127

Showing 1-25 of 127 citing articles:

Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies
Suowen Xu, Iqra Ilyas, Jianping Weng
Acta Pharmacologica Sinica (2022) Vol. 44, Iss. 4, pp. 695-709
Open Access | Times Cited: 278
Mechanisms of action of fluvoxamine for COVID-19: a historical review
Yaeko Hashimoto, Takuji Suzuki, Kenji Hashimoto
Molecular Psychiatry (2022) Vol. 27, Iss. 4, pp. 1898-1907
Open Access | Times Cited: 109
Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization
Todd C. Lee, Simone N. Vigod, Émilie Bortolussi‐Courval, et al.
JAMA Network Open (2022) Vol. 5, Iss. 4, pp. e226269-e226269
Open Access | Times Cited: 62
Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis
Jiawen Deng, Daniel Rayner, Harikrishnaa Ba Ramaraju, et al.
Clinical Microbiology and Infection (2023) Vol. 29, Iss. 5, pp. 578-586
Open Access | Times Cited: 23
Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19
Hythem Sidky, Kristen Hansen, Andrew T. Girvin, et al.
Computational and Structural Biotechnology Journal (2024) Vol. 24, pp. 115-125
Open Access | Times Cited: 15
Harnessing EHR data for health research
Alice Tang, Sarah Woldemariam, Silvia Miramontes, et al.
Nature Medicine (2024) Vol. 30, Iss. 7, pp. 1847-1855
Closed Access | Times Cited: 9
Do the Selective Serotonin Reuptake Inhibitor Antidepressants Fluoxetine and Fluvoxamine Reduce Mortality Among Patients With COVID-19?
Nicolas Hoertel
JAMA Network Open (2021) Vol. 4, Iss. 11, pp. e2136510-e2136510
Open Access | Times Cited: 43
Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19
Mohamed Mahdi, Levente Hermán, János Réthelyi, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3812-3812
Open Access | Times Cited: 33
Lipid rafts as viral entry routes and immune platforms: A double-edged sword in SARS-CoV-2 infection?
Rossana Roncato, Jacopo Angelini, Arianna Pani, et al.
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids (2022) Vol. 1867, Iss. 6, pp. 159140-159140
Open Access | Times Cited: 31
Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study
Nicolas Hoertel, Marina Sánchez‐Rico, Erich Gulbins, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 31
Occurrence and fate of antidepressants in the aquatic environment: Insights into toxicological effects on the aquatic life, analytical methods, and removal techniques
Adarsh Singh, Duduku Saidulu, Ashok Kumar Gupta, et al.
Journal of environmental chemical engineering (2022) Vol. 10, Iss. 6, pp. 109012-109012
Closed Access | Times Cited: 30
Association Between the Use of Psychotropic Medications and the Risk of COVID-19 Infection Among Long-term Inpatients With Serious Mental Illness in a New York State–wide Psychiatric Hospital System
Katlyn Nemani, Sharifa Z. Williams, Mark Olfson, et al.
JAMA Network Open (2022) Vol. 5, Iss. 5, pp. e2210743-e2210743
Open Access | Times Cited: 29
Sigma-1 Receptor Signaling: In Search of New Therapeutic Alternatives for Cardiovascular and Renal Diseases
Francisco Javier Munguía-Galaviz, Alejandra Guillermina Miranda‐Díaz, Miguel Alejandro Cardenas-Sosa, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 1997-1997
Open Access | Times Cited: 22
Overview of the potential use of fluvoxamine for COVID-19 and long COVID
Kenji Hashimoto
Discover Mental Health (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 20
The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis
Hosein Nakhaee, Moein Zangiabadian, R. Bayati, et al.
PLoS ONE (2022) Vol. 17, Iss. 10, pp. e0267423-e0267423
Open Access | Times Cited: 26
Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19
Nicolas Hoertel, Marina Sánchez‐Rico, Johannes Kornhuber, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 19, pp. 5882-5882
Open Access | Times Cited: 24
Antidepressants for COVID-19: A systematic review
Wei Zheng, Heli Sun, Hong Cai, et al.
Journal of Affective Disorders (2022) Vol. 307, pp. 108-114
Open Access | Times Cited: 23
Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2
Bradley A. Fritz, Nicolas Hoertel, Eric J. Lenze, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 23
Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities
Mohammad Shah Alam
Heliyon (2023) Vol. 9, Iss. 2, pp. e13285-e13285
Open Access | Times Cited: 16
Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study)
Taweegrit Siripongboonsitti, Teerapat Ungtrakul, Kriangkrai Tawinprai, et al.
International Journal of Infectious Diseases (2023) Vol. 134, pp. 211-219
Open Access | Times Cited: 15
SSRIs differentially modulate the effects of pro-inflammatory stimulation on hippocampal plasticity and memory via sigma 1 receptors and neurosteroids
Yukitoshi Izumi, Angela M. Reiersen, Eric J. Lenze, et al.
Translational Psychiatry (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 14
Sertraline modulates hippocampal plasticity via sigma 1 receptors, cellular stress and neurosteroids
Yukitoshi Izumi, Angela M. Reiersen, Eric J. Lenze, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
COVID-19 Outcomes: Does the Use of Psychotropic Drugs Make a Difference? Accumulating Evidence of a Beneficial Effect of Antidepressants—A Scoping Review
Udo Bonnet, Georg Juckel
Journal of Clinical Psychopharmacology (2022) Vol. 42, Iss. 3, pp. 284-292
Open Access | Times Cited: 22
Antiviral and Anti-Inflammatory Activities of Fluoxetine in a SARS-CoV-2 Infection Mouse Model
David Péricat, Stephen Adonai Leon‐Icaza, Marina Sánchez‐Rico, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13623-13623
Open Access | Times Cited: 22
Metabolic rewiring and serotonin depletion in patients with postacute sequelae of COVID‐19
Corinna Sadlier, Werner C. Albrich, Ujjwal Neogi, et al.
Allergy (2022) Vol. 77, Iss. 5, pp. 1623-1625
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top